This announcement is a separate document:
Elicio Therapeutics | DEF 14A: Definitive information statements
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Symbol Mini Chart Price
Unlock the Full List
Latest
17:07
Bank of America Global Fund Manager Survey: The most crowded trades are going long on the 'Seven Giants of Wall Street' (53%), going long on the dollar (27%), and going long on Cryptos (13%); investors are returning to large-cap stocks, with few believing value stocks will outperform growth stocks.
BAC-0.24%
17:07
New impetus: Expected net profit loss of 55 million yuan to 75 million yuan in 2024
Xiong'an New Power Technology-1.83%
17:07
UMC's net profit for the year is NT$47.21 billion, and the market estimates are NT$50.7 billion. Operating profit for the year was NT$51.61 billion, and the market estimate was NT$52.03 billion. Annual revenue is NT$232.3 billion, and the market estimates are NT$231.71 billion.
UMC+1.13%